Rethinking surgical care in confl ict
The provision of surgical assistance in confl ict is often associated with care for victims of violence. Images of the war wounded from bullets, bomb-blasts, and other violent assaults often feature prominently in the mass media. The discipline has been guided by military surgeons from the developed world who aim to develop approaches that use the latest surgical technologies in war zones.
1,2 However, in many confl icts, the bulk of surgical care is provided by non-military actors, including humanitarian organisations, who work with more limited resources. 3 Injury during confl ict contributes to substantial mortality, but major causes of excess mortality are often secondary: cholera, measles, and malnutrition are all exacerbated by mass population-displacements and overcrowded conditions for refugees. 4, 5 Similarly, surgical needs in confl ict extend well beyond trauma: mortality from infection, poor nutrition, obstetric emergencies, and accidental injuries are all amenable to surgical intervention. A recent study from the Democratic Republic of Congo found that mortality from obstetric emergencies and accidental injury in confl ict was four times higher than that from violence. 5 In general, maternal and child mortality is higher in confl ict-aff ected and post-confl ict countries than in least-developed countries not directly aff ected by confl ict. 6 Surgical projects in confl icts rarely collect reliable statistics, but operational data suggests that civilian surgical needs are predominantly not related to combat. A retrospective review of surgical services of Médecins Sans Frontières in six confl ict settings found that only 22% (1050) of 4630 surgical interventions were due to violent injury. Violence represented less than half of all surgical interventions in confl ict-aff ected areas in Pakistan (5%), South Sudan (21%), Chad (36%), and Somalia (41%). At almost all sites, obstetric emergencies vastly outnumbered the war-wounded, accounting for almost a third (30%) of all interventions, while accidental injury and tropical infections accounted for another third.
The fact that war-wounded often represent a minority of surgical needs is not suffi ciently appreciated. A sevencountry review of health services for displaced populations found that not a single camp had an operating theatre that could provide life-saving surgery, such as caesarean section or bowel-rupture repair. 7 Other likely needs include an increase in complications of untreated infectious diseases, such as bowel perforation from typhoid fever and soft-tissue abscesses. Limiting surgical humanitarian assistance to the war-wounded will lead to partial needsassessments, and inadequate programme-planning and provision of supplies and human resources. Part of the problem is a lack of reliable data on the surgical burden of disease in confl ict settings. No large population-based surveys have been published, and the few programme data that exist tend to refl ect availability of services rather than population needs. Without reliable survey data, we cannot know whether an increased caseload refl ects an increased disease burden related to the confl ict (more road-traffi c accidents as people fl ee confl ict) or an underlying need that can no longer be met due to destruction of and limited access to health services.
The bias towards violence-related surgery is refl ected in the research fi eld, which has largely focused on the specialised surgical care of trauma. 8 In view of the dire shortage of surgeons in resource-limited settings, more emphasis should be placed on operational research to support the provision of essential surgical care by general doctors or non-physician clinicians, particularly because most essential surgical procedures required in confl ictaff ected zones are relatively simple interventions. 9 Whereas the emergency public health response to infec tious diseases and malnutrition during confl ict is well developed, 7 humanitarian practice-guidelines take a narrow view of surgical needs. The Sphere Project, an inter agency eff ort dedicated to establishing minimum standards of humanitarian assistance for disaster response, limits its guidance for surgical programming to trauma and obstetric care. 10 These guidelines are under review, which presents an opportunity to more comprehensively address surgical needs in confl ict and postconfl ict settings.
Services to support general surgery in confl ict settings are lacking mainly because most confl icts occur in leastdeveloped countries where surgical capacity is severely limited: the poorest third of countries benefi t from only 3·5% of global surgical interventions. 11 With a growing appreciation of the substantial burden of surgical diseases across the developing world, 12 the relevance of the traditional models of surgical assistance for civilians in confl ict merits reconsideration.
Ticagrelor in ACS: redefi ning a new standard of care?
Tremendous progress has been achieved over the past decade in the treatment of acute coronary syndromes (ST-segment elevation myocardial infarction [STEMI], non-STEMI [NSTEMI], and unstable angina). In STEMI, primary percutaneous coronary intervention compared with fi brinolytic therapy reduces mortality, reinfarction, stroke, infarct size, and recurrent ischaemia.
1
In moderate-risk and high-risk patients with NSTEMI, early angiography followed by revascularisation with either percutaneous coronary intervention or coronary artery bypass graft surgery compared with a more conservative approach reduces the rates of death or myocardial infarction, recurrent ischaemia, and rehospitalisation. 2, 3 Drug-eluting stents have been shown to be safe in acute coronary syndromes, and, compared with bare-metal stents, reduce clinical and angiographic restenosis, 4 further improving quality of life. With expeditious revascularisation recognised as the cornerstone of the treatment of acute coronary syndromes, selecting the optimum pharmacotherapeutic regimen to support the invasive approach becomes imperative. Because platelet activation is intense in acute coronary syndromes, percutaneous coronary intervention, and coronary artery bypass graft surgery, it is not surprising that the thienopyridine clopidogrel, which inhibits ADP-induced platelet activation, when added to aspirin further suppresses ischaemic complications in acute coronary syndromes. 5, 6 Prasugrel, which is more potent and rapidacting than clopidogrel, is even better at preventing myocardial infarction and stent thrombosis in patients with an acute coronary syndrome undergoing percutaneous coronary intervention. 7 However, proportional to their potency, these oral agents increase haemorrhagic complications, the occurrence of which has been strongly linked to subsequent mortality. 8, 9 As a result, neither thienopyridine has been shown to improve survival in acute coronary syndromes.
Enter ticagrelor, an oral non-thienopyridine cyclo-pentyltriazolo-pyrimidine ADP-receptor (P2Y12 ant agonist, which like prasugrel is more potent and rapid-acting than clopidogrel. In the PLATO trial, this agent was compared with clopidogrel in more than 18 500 patients with acute coronary syndromes. 10 In The Lancet, today, the PLATO investigators 11 now report the detailed outcomes in around 13 000 patients (72·0% of all those enrolled) managed with an urgent early invasive approach. Like prasugrel, ticagrelor compared with clopidogrel signifi cantly reduced rates of myocardial infarction and stent thrombosis, accompanied by an increase in major bleeding that was unrelated to coronary artery bypass graft surgery. However, that is where the comparison ends. In TRITON, prasugrel increased bleeding that was related to coronary artery bypass graft surgery, all-cause bleeding, and transfusions, as well as life-threatening and fatal bleeding which largely off set its expected benefi ts from prevention of myocardial infarction and stent thrombosis. As a result, total mortality at 15 months was not signifi cantly diff erent with prasugrel and clopidogrel
